Targeting the diverse immunological functions expressed by hepatic NKT cells

Expert Opinion on Therapeutic Targets

Volumn 15, Issue 8, 2011, Pages 973-988

  Duwaerts, Caroline C ^a   Gregory, Stephen H ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

galactosylceramide; CD1d; Interferon ; Interleukin 4; Liver; NKT cell

Indexed keywords

1 O (ALPHA GALACTOPYRANOSYL) 2 HEXACOSANOYLAMINO 1,3,4 OCTADECANETRIOL; ALCOHOL; ALPHA GALACTOSYLCERAMIDE; ALPHA GALACTOSYLCERAMIDE DERIVATIVE; CARBOHYDRATE DERIVATIVE; GAMMA INTERFERON; GLYCOSIDIC BOND DERIVATIVE; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 12 RECEPTOR; INTERLEUKIN 12P40; INTERLEUKIN 13; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; SPHINGOSINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALCOHOL LIVER DISEASE; ANTIBACTERIAL ACTIVITY; ANTIPROTOZOAL ACTIVITY; ANTIVIRAL ACTIVITY; AUTOIMMUNE HEPATITIS; AUTOIMMUNITY; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; DRUG STRUCTURE; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNOSURVEILLANCE; INTRAHEPATIC CHOLESTASIS; LIVER DISEASE; LIVER ISCHEMIA; LIVER METASTASIS; LIVER REGENERATION; LIVER TOXICITY; NATURAL KILLER T CELL; NONALCOHOLIC FATTY LIVER; NONHUMAN; PARTIAL HEPATECTOMY; PHASE 1 CLINICAL TRIAL (TOPIC); PRIMARY BILIARY CIRRHOSIS; REPERFUSION INJURY; REVIEW; TH1 CELL; TH2 CELL; TUMOR REJECTION;

ANIMALS; HUMANS; KILLER CELLS, NATURAL; LIVER; MICE; MICE, KNOCKOUT;

EID: 79960282665     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2011.584874     Document Type: Review

References (121)

1. Taniguchi M, Harada M, Kojo S, et al. The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu Rev Immunol 2003;15:483-513 (Pubitemid 37174539)
2. Fujii S, Shimizu K, Smith C, et al. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med 2003;198:267-79 (Pubitemid 36987852)
3. Geissmann F, Cameron TO, Sidobre S, et al. Intravascular immune surveillance by CXCR6+ NKT cells patrolling liver sinusoids. PLoS Biol 2005;3(4):e113
4. Norris S, Doherty DG, Collins C, et al. Natural T cells in the human liver: cytotoxic lymphocytes with dual T cell and natural killer cell phenotype and function are phenotypically heterogenous and include Va24-JaQ and gd T cell receptor bearing cells. Hum Immunol 1999;60:20-31 (Pubitemid 29057853)
5. Hammond KJL, Pellicci DG, Poulton LD, et al. CD1d-restricted NKT cells: an interstrain comparison. J Immunol 2001;167:1164-73 (Pubitemid 32703109)
6. Lantz O, Bendelac A. An invariant T cell receptor a chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8- T cells in mice and humans. J Exp Med 1994;180:1097-106 (Pubitemid 24256622)
7. Doherty DG, O'Farrelly C. Innate and adaptive lymphoid cells in the human liver. Immunol Rev 2000;174:5-20 (Pubitemid 30201375)
8. Brigl M, Brenner MB. CD1: antigen presentation and T cell function. Annu Rev Immunol 2004;22:817-90 (Pubitemid 38680443)
9. Godfrey DI, MacDonald HR, Kronenberg M, et al. NKT cells: what's in a name? Nat Rev Immunol 2004;4:231-7 (Pubitemid 38339089)
10. Benlagha K, Weiss A, Beavis A, et al. In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers. J Exp Med 2000;191:1895-903 (Pubitemid 30390352)
11. Porcelli SA. The CD1 family: a third lineage of antigen-presenting molecules. Adv Immunol 1995;59:1-98
12. Tourne S, Maitre B, Collmann A, et al. Cutting edge: a naturally occurring mutation in CD1e impairs lipid antigen presentation. J Immunol 2008;180:3642-6
13. Mandal M, Chen XR, Alegre ML, et al. Tissue distribution, regulation and intracellular localization of murine CD1 molecules. Mol Immunol 1998;35:525-36 (Pubitemid 28480198)
14. Zeng Z, Castano AR, Segelke BW, et al. Crystal structure of mouse CD1: An MHC-like fold with a large hydrophobic binding groove. Science 1997;277:339-45 (Pubitemid 27450700)
15. Berzins SP, Smyth MJ, Baxter AG. Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol 2011;11:131-42
16. Notas G, Kisseleva T, Brenner D. NK and NKT cells in liver injury and fibrosis. Clin Immunol 2009;130:16-26
17. Kenna T, Golden-Mason L, Porcelli SA, et al. NKT cells from normal and tumor-bearing human livers are phenotypically and functionally distinct from murine NKT cells. J Immunol 2003;171:1775-9 (Pubitemid 36969796)
18. Seki S, Hashimoto W, Ogasawara K, et al. Antimetastatic effect of NK1+ T cells on experimental haematogenous tumour metastases in the liver and lungs of mice. Immunology 1997;92:561-6 (Pubitemid 27525229)
19. Cui J, Shin T, Kawano T, et al. Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 1997;278:1623-6 (Pubitemid 27516281)
20. Kinjo Y, Kronenberg M. Valpha14i NKT cells are innate lymphocytes that participate in the immune response to diverse microbes. J Clin Immunol 2005;25:522-33 (Pubitemid 43011744)
21. Brigl M, Bry L, Kent SC, et al. Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat Immunol 2003;4:1230-7 (Pubitemid 37540692)
22. Mattner J, Debord KL, Ismail N, et al. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 2005;434:525-9 (Pubitemid 40477062)
23. Kinjo Y, Wu D, Kim G, et al. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 2005;434:520-5 (Pubitemid 40477061)
24. Behar SM, Dascher CC, Grusby MJ, et al. Susceptibility of mice deficient in CD1D or TAP1 to infection with Mycobacterium tuberculosis. J Exp Med 1999;189:1973-80 (Pubitemid 29295896)
25. Dieli F, Taniguchi M, Kronenberg M, et al. An anti-inflammatory role for Valpha14 NK T cells in Mycobacterium bovis bacillus Calmette-Guerin-infected mice. J Immunol 2003;171:1961-8 (Pubitemid 36966480)
26. Ishigami M, Nishimura H, Naiki Y, et al. The roles of intrahepatic Valpha14+ NK1.1+ T cells for liver injury induced by Salmonella infection in mice. Hepatology 1999;29:1799-808 (Pubitemid 29247054)
27. Hiromatsu T, Matsuguchi T, Shimizu H, et al. NK T cells stimulated with a ligand for TLR2 at least partly contribute to liver injury caused by Escherichia coli infection in mice. Eur J Immunol 2003;33:2511-19 (Pubitemid 37138983)
28. Rhee RJ, Carlton S, Lomas JL, et al. Inhibition of CD1d activation suppresses septic mortality: a role for NK-T cells in septic immune dysfunction. J Surg Res 2003;115:74-81 (Pubitemid 37323951)
29. Hu CK, Venet F, Heffernan DS, et al. The role of hepatic invariant NKT cells in systemic/local inflammation and mortality during polymicrobial septic shock. J Immunol 2009;182:2467-75
30. Etogo AO, Nunez J, Lin CY, et al. NK but not CD1-restricted NKT cells facilitate systemic inflammation during polymicrobial intra-abdominal sepsis. J Immunol 2008;180:6334-45
31. Gregory SH, Barczynski LK, Wing EJ. Effector function of hepatocytes and Kupffer cells in the resolution of systemic bacterial infections. J Leukocyte Biol 1992;51:421-4
32. Emoto M, Yoshizawa I, Emoto Y, et al. Rapid development of a gamma interferon-secreting glycolipid/CD1dspecific Valpha14+ NK1.1- T-cell subset after bacterial infection. Infect Immun 2006;74:5903-13 (Pubitemid 44484578)
33. Szalay G, Ladel CH, Blum C, et al. Cutting edge: anti-CD1 monoclonal antibody treatment reverses the production patterns of TGF-beta2 and Th1 cytokines and ameliorates listeriosis in mice. J Immunol 1999;162:6955-8 (Pubitemid 29277657)
34. Arrunategui-Correa V, Kim HS. The role of CD1d in the immune response against Listeria infection. Cell Immunol 2004;227:109-20 (Pubitemid 38595383)
35. Nieuwenhuis EE, Matsumoto T, Lindenbergh D, et al. Cd1d-dependent regulation of bacterial colonization in the intestine of mice. J Clin Invest 2009;119:1241-50
36. Spence PM, Sriram V, van Kaer L, et al. Generation of cellular immunity to lymphocytic choriomeningitis virus is independent of CD1d1 expression. Immunology 2001;104:168-74 (Pubitemid 32989518)
37. Wesley JD, Tessmer MS, Chaukos D, et al. NK cell-like behavior of Va14i NK T cells during MCMV infection. PLoS Pathog 2008;4(7):e1000106
38. Parker AK, Parker S, Yokoyama WM, et al. Induction of natural killer cell responses by ectromelia virus controls infection. J Virol 2007;81:4070-9 (Pubitemid 46586902)
39. Ajuebor MN, Chen Q, Strieter RM, et al. Valpha14iNKT cells promote liver pathology during adenovirus infection by inducing CCL5 production: implications for gene therapy. J Virol 2010;84:8520-9
40. Durante-Mangoni E, Wang R, Shaulov A, et al. Hepatic CD1d expression in hepatitis C virus infection and recognition by resident proinflammatory CD1d-reactive T cells. J Immunol 2004;173:2159-66 (Pubitemid 38971655)
41. Deignan T, Curry MP, Doherty DG, et al. Decrease in hepatic CD56+ T cells and Valpha24+ natural killer T cells in chronic hepatitis C viral infection. J Hepatol 2002;37:101-8 (Pubitemid 34713061)
42. Nuti S, Rosa D, Valiante NM, et al. Dynamics of intra-hepatic lymphocytes in chronic hepatitis C: enrichment for Valpha24+ T cells and rapid elimination of effector cells by apoptosis. Eur J Immunol 1998;28:3448-55 (Pubitemid 28510755)
43. de Lalla C, Galli G, Aldrighetti L, et al. Production of profibrotic cytokines by invariant NKT cells characterizes cirrhosis progression in chronic viral hepatitis. J Immunol 2004;173:1417-25 (Pubitemid 38924323)
44. Yamagiwa S, Matsuda Y, Ichida T, et al. Sustained response to interferon-alpha plus ribavirin therapy for chronic hepatitis C is closely associated with increased dynamism of intrahepatic natural killer and natural killer T cells. Hepatol Res 2008;38:664-72 (Pubitemid 351784979)
45. Amprey JL, Im JS, Turco SJ, et al. A subset of liver NK T cells is activated during Leishmania donovani infection by CD1d-bound lipophosphoglycan. J Exp Med 2004;200:895-904 (Pubitemid 39362925)
46. Mattner J, Donhauser N, Werner-Felmayer G, et al. NKT cells mediate organ-specific resistance against Leishmania major infection. Microbes Infect 2006;8:354-62 (Pubitemid 43214597)
47. Stanley AC, Zhou Y, Amante FH, et al. Activation of invariant NKT cells exacerbates experimental visceral leishmaniasis. PLoS Pathog 2008;4(2):e1000028
48. Soulard V, Roland J, Sellier C, et al. Primary infection of C57BL/6 mice with Plasmodium yoelii induces a heterogeneous response of NKT cells. Infect Immun 2007;75:2511-22 (Pubitemid 46744343)
49. Gonzalez-Aseguinolaza G, de Oliveira C, Tomaska M, et al. alpha-Galactosylceramide-activated Valpha14 natural killer T cells mediate protection against murine malaria. Proc Natl Acad Sci USA 2000;97:8461-6 (Pubitemid 30639695)
50. Romero JF, Eberl G, MacDonald HR, et al. CD1d-restricted NK T cells are dispensable for specific antibody responses and protective immunity against liver stage malaria infection in mice. Parasite Immunol 2001;23:267-9 (Pubitemid 34205683)
51. Duthie MS, Kahn M, White M, et al. Critical proinflammatory and anti-inflammatory functions of different subsets of CD1d-restricted natural killer T cells during Trypanosoma cruzi infection. Infect Immun 2005;73:181-92 (Pubitemid 40041108)
52. Chernavsky AC, Paladino N, Rubio AE, et al. Simultaneous expression of Th1 cytokines and IL-4 confers severe characteristics to type I autoimmune hepatitis in children. Hum Immunol 2004;65:683-91 (Pubitemid 39061164)
53. Zhu R, Diem S, Araujo LM, et al. The pro-Th1 cytokine IL-12 enhances IL-4 production by invariant NKT cells: relevance for T cell-mediated hepatitis. J Immunol 2007;178:5435-42 (Pubitemid 46674337)
54. Takeda K, Hayakawa Y, van Kaer L, et al. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc Natl Acad Sci USA 2000;97:5498-503 (Pubitemid 30313747)
55. Harada K, Isse K, Tsuneyama K, et al. Accumulating CD57+CD3+ natural killer T cells are related to intrahepatic bile duct lesions in primary biliary cirrhosis. Liver Int 2003;23:94-100 (Pubitemid 37265780)
56. Kaplan MM. Novosphingobium aromaticivorans: a potential initiator of primary biliary cirrhosis. Am J Gastroenterol 2004;99:2147-9 (Pubitemid 39524705)
57. Mattner J, Savage PB, Leung P, et al. Liver autoimmunity triggered by microbial activation of natural killer T cells. Cell Host Microbe 2008;3:304-15 (Pubitemid 351637431)
58. Wintermeyer P, Cheng CW, Gehring S, et al. Invariant natural killer T cells suppress the neutrophil inflammatory response in a mouse model of cholestatic liver damage. Gastroenterology 2009;136:1048-59
59. Park O, Jeong WI, Wang L, et al. Diverse roles of invariant natural killer T cells in liver injury and fibrosis induced by carbon tetrachloride. Hepatology 2009;49:1683-94
60. Minagawa M, Oya H, Yamamoto S, et al. Intensive expansion of natural killer T cells in the early phase of hepatocyte regeneration after partial hepatectomy in mice and its association with sympathetic nerve activation. Hepatology 2000;31:907-15 (Pubitemid 30169938)
61. Nakashima H, Inui T, Habu Y, et al. Activation of mouse natural killer T cells accelerates liver regeneration after partial hepatectomy. Gastroenterology 2006;131:1573-83 (Pubitemid 44708934)
62. Kato T, Sato Y, Takahashi S, et al. Involvement of natural killer T cells and granulocytes in the inflammation induced by partial hepatectomy. J Hepatol 2004;40:285-90 (Pubitemid 38115834)
63. Shimamura K, Kawamura H, Nagura T, et al. Association of NKT cells and granulocytes with liver injury after reperfusion of the portal vein. Cell Immunol 2005;234:31-8 (Pubitemid 41140389)
64. Lappas CM, Day YJ, Marshall MA, et al. Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. J Exp Med 2006;203:2639-48 (Pubitemid 44833340)
65. Minagawa M, Deng Q, Liu ZX, et al. Activated natural killer T cells induce liver injury by Fas and tumor necrosis factor-alpha during alcohol consumption. Gastroenterology 2004;126:1387-99 (Pubitemid 38552802)
66. Tajiri K, Shimizu Y, Tsuneyama K, et al. Role of liver-infiltrating CD3+CD56+ natural killer T cells in the pathogenesis of nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2009;21:673-80
67. Natori T, Koezuka Y, Higa T. Agelasphins, novel a-galactosylceramides from the marine sponge Agelas mauritanus. Tetrahedron Lett 1993;34:5591-2
68. Kobayashi E, Motoki K, Uchida T, et al. KRN7000, a novel immunomodulator, and its antitumor activities. Oncol Res 1995;7:529-34 (Pubitemid 26077987)
69. Kawano T, Cui J, Koezuka Y, et al. CD1d-restricted and TCR-mediated activation of Valpha14 NKT cells by glycosylceramides. Science 1997;278:1626-9 (Pubitemid 27516282)
70. Koch M, Stronge VS, Shepherd D, et al. The crystal structure of human CD1d with and without alpha-galactosylceramide. Nat Immunol 2005;6:819-26 (Pubitemid 43090468)
71. van Kaer L. alpha-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nat Rev Immunol. 2005; 5: 31-42. (Pubitemid 40070329)
72. Miyamoto K, Miyake S, Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 2001;413:531-4 (Pubitemid 32938752)
73. Oki S, Chiba A, Yamamura T, et al. The clinical implication and molecular mechanism of preferential IL-4 production by modified glycolipid-stimulated NKT cells. J Clin Invest 2004;113:1631-40 (Pubitemid 39071687)
74. Carnaud C, Lee D, Donnars O, et al. Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol 1999;163:4647-50 (Pubitemid 29501223)
75. Parekh VV, Singh AK, Wilson MT, et al. Quantitative and qualitative differences in the in vivo response of NKT cells to distinct alpha- and beta-anomeric glycolipids. J Immunol 2004;173:3693-706 (Pubitemid 39280730)
76. Ilan Y. Alpha versus beta: are we on the way to resolve the mystery as to which is the endogenous ligand for natural killer T cells? Clin Exp Immunol 2009;158:300-7
77. Im JS, Arora P, Bricard G, et al. Kinetics and cellular site of glycolipid loading control the outcome of natural killer T cell activation. Immunity 2009;30:888-98
78. Wu D, Zajonc DM, Fujio M, et al. Design of natural killer T cell activators: structure and function of a microbial glycosphingolipid bound to mouse CD1d. Proc Natl Acad Sci USA 2006;103:3972-7
79. Tatsumi T, Takehara T, Miyagi T, et al. alpha-Galactosylceramide activates antitumor immunity against liver tumor. Hepatol Res 2011;41:160-9
80. Tatsumi T, Takehara T, Yamaguchi S, et al. Intrahepatic delivery of alpha-galactosylceramide-pulsed dendritic cells suppresses liver tumor. Hepatology 2007;45:22-30 (Pubitemid 46144361)
81. Nakagawa R, Motoki K, Nakamura H, et al. Antitumor activity of alpha-galactosylceramide, KRN7000, in mice with EL-4 hepatic metastasis and its cytokine production. Oncol Res 1998;10:561-8
82. Smyth MJ, Crowe NY, Pellicci DG, et al. Sequential production of interferon-gamma by NK1.1+ T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide. Blood 2002;99:1259-66 (Pubitemid 34547079)
83. Osada T, Nagawa H, Shibata Y. Tumor-infiltrating effector cells of alpha-galactosylceramide-induced antitumor immunity in metastatic liver tumor. J Immune Based Ther Vaccines 2004;2(1):7
84. Nieda M, Okai M, Tazbirkova A, et al. Therapeutic activation of Valpha24+ Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 2004;103:383-9 (Pubitemid 38140063)
85. Kakimi K, Guidotti LG, Koezuka Y, et al. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med 2000;192:921-30
86. Ito H, Ando K, Ishikawa T, et al. Role of Valpha14+ NKT cells in the development of hepatitis B virus-specific CTL: activation of Valpha14+ NKT cells promotes the breakage of CTL tolerance . Int Immunol 2008;20:869-79 (Pubitemid 351865862)
87. Albarran B, Goncalves L, Salmen S, et al. Profiles of NK, NKT cell activation and cytokine production following vaccination against hepatitis B. APMIS 2005;113:526-35 (Pubitemid 41081477)
88. Schneiders FL, Scheper RJ, von Blomberg BM, et al. Clinical experience with alpha-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection. Clin Immunol 2010: published online 18 December 2010, doi:10.1016/j.clim.2010.11.010
89. Veldt BJ, van der Vliet HJ, von Blomberg BM, et al. Randomized placebo controlled phase I/II trial of alpha-galactosylceramide for the treatment of chronic hepatitis C. J Hepatol 2007;47:356-65 (Pubitemid 47176162)
90. Woltman AM, Ter Borg MJ, Binda RS, et al. alpha-galactosylceramide in chronic hepatitis B infection: results from a randomized placebo-controlled Phase I/II trial. Antivir Ther 2009;14:809-18
91. van Dommelen SL, Tabarias HA, Smyth MJ, et al. Activation of natural killer (NK) T cells during murine cytomegalovirus infection enhances the antiviral response mediated by NK cells. J Virol 2003;77:1877-84 (Pubitemid 36110000)
92. Emoto M, Emoto Y, Yoshizawa I, et al. alpha-GalCer ameliorates listeriosis by accelerating infiltration of Gr-1+ cells into the liver. Eur J Immunol 2010;40:1328-41
93. Cao Z, Yuan Y, Jeyabalan G, et al. Preactivation of NKT cells with a-GalCer protects against hepatic ischemia-reperfusion injury in mouse by a mechanism involving IL-13 and adenosine A2A receptor. Am J Physiol Gastrointest Liver Physiol 2009;297:G249-58
94. Ito H, Ando K, Nakayama T, et al. Role of Valpha14 NKT cells in the development of impaired liver regeneration in vivo. Hepatology 2003;38:1116-24 (Pubitemid 37314820)
95. Safadi R, Zigmond E, Pappo O, et al. Amelioration of hepatic fibrosis via beta-glucosylceramide-mediated immune modulation is associated with altered CD8 and NKT lymphocyte distribution. Int Immunol 2007;19:1021-9 (Pubitemid 47386927)
96. Lalazar G, Preston S, Zigmond E, et al. Glycolipids as immune modulatory tools. Mini Rev Med Chem 2006;6:1249-53 (Pubitemid 44697104)
97. Biburger M, Tiegs G. alpha-Galactosylceramide-induced liver injury in mice is mediated by TNF-alpha but independent of Kupffer cells. J Immunol 2005;175:1540-50 (Pubitemid 41023055)
98. Schiefner A, Fujio M, Wu D, et al. Structural evaluation of potent NKT cell agonists: implications for design of novel stimulatory ligands. J Mol Biol 2009;394:71-82
99. Bai L, Sagiv Y, Liu Y, et al. Lysosomal recycling terminates CD1d-mediated presentation of short and polyunsaturated variants of the NKT cell lipid antigen alphaGalCer. Proc Natl Acad Sci USA 2009;106:10254-9
100. Schmieg J, Yang G, Franck RW, et al. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-galactosylceramide. J Exp Med 2003;198:1631-41 (Pubitemid 37494156)
101. Fujii S, Shimizu K, Hemmi H, et al. Glycolipid alpha-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice. Proc Natl Acad Sci USA 2006;103:11252-7 (Pubitemid 44156505)
102. Goff RD, Gao Y, Mattner J, et al. Effects of lipid chain lengths in alpha-galactosylceramides on cytokine release by natural killer T cells. J Am Chem Soc 2004;126:13602-3 (Pubitemid 39407224)
103. Mizuno M, Masumura M, Tomi C, et al. Synthetic glycolipid OCH prevents insulitis and diabetes in NOD mice. J Autoimmun 2004;23:293-300 (Pubitemid 39574804)
104. Chiba A, Oki S, Miyamoto K, et al. Suppression of collagen-induced arthritis by natural killer T cell activation with OCH, a sphingosine-truncated analog of alpha-galactosylceramide. Arthritis Rheum 2004;50:305-13 (Pubitemid 38084316)
105. Chang YJ, Huang JR, Tsai YC, et al. Potent immune-modulating and anticancer effects of NKT cell stimulatory glycolipids. Proc Natl Acad Sci USA 2007;104:10299-304
106. Yu KO, Im JS, Molano A, et al. Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of alpha-galactosylceramides. Proc Natl Acad Sci USA 2005;102:3383-8 (Pubitemid 40328054)
107. Lang GA, Maltsev SD, Besra GS, et al. Presentation of alpha-galactosylceramide by murine CD1d to natural killer T cells is facilitated by plasma membrane glycolipid rafts. Immunology 2004;112:386-96 (Pubitemid 38859516)
108. Zajonc DM, Kronenberg M. Carbohydrate specificity of the recognition of diverse glycolipids by natural killer T cells. Immunol Rev 2009;230:188-200
109. Venkataswamy MM, Porcelli SA. Lipid and glycolipid antigens of CD1d-restricted natural killer T cells. Semin Immunol 2010;22:68-78
110. Trappeniers M, Van Beneden K, Decruy T, et al. 6'-derivatised alpha-GalCer analogues capable of inducing strong CD1d-mediated Th1-biased NKT cell responses in mice. J Am Chem Soc 2008;130:16468-9
111. Tashiro T, Nakagawa R, Hirokawa T, et al. RCAI-37, 56, 59, 60, 92, 101, and 102, cyclitol and carbasugar analogs of KRN7000: their synthesis and bioactivity for mouse lymphocytes to produce Th1-biased cytokines. Bioorg Med Chem 2009;17:6360-73
112. Zigmond E, Preston S, Pappo O, et al. beta-Glucosylceramide: a novel method for enhancement of natural killer T lymphocyte plasticity in murine models of immune-mediated disorders. Gut 2007;56:82-9 (Pubitemid 46044892)
113. Lalazar G, Ben Ya'acov A, Lador A, et al. Modulation of intracellular machinery by beta-glycolipids is associated with alteration of NKT lipid rafts and amelioration of concanavalin-induced hepatitis. Mol Immunol 2008;45:3517-25
114. Sheth K, Bankey P. The liver as an immune organ. Curr Opin Crit Care 2001;7:99-104 (Pubitemid 32411398)
115. Crispe IN, Giannandrea M, Klein I, et al. Cellular and molecular mechanisms of liver tolerance. Immunol Rev 2006;213:101-18 (Pubitemid 44401496)
116. Lucas M, Gadola S, Meier U, et al. Frequency and phenotype of circulating Valpha24/Vbeta11 double-positive natural killer T cells during hepatitis C virus infection. J Virol 2003;77:2251-7 (Pubitemid 36110039)
117. Tsuneyama K, Yasoshima M, Harada K, et al. Increased CD1d expression on small bile duct epithelium and epithelioid granuloma in livers in primary biliary cirrhosis. Hepatology 1998;28:620-3 (Pubitemid 28405406)
118. Kita H, Naidenko OV, Kronenberg M, et al. Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer. Gastroenterology 2002;123:1031-43
119. Wondimu Z, Santodomingo-Garzon T, Le T, et al. Protective role of interleukin-17 in murine NKT cell-driven acute experimental hepatitis. Am J Pathol 2010;177:2334-46
120. Kato A, Yoshidome H, Edwards MJ, et al. Reduced hepatic ischemia/ reperfusion injury by IL-4: potential anti-inflammatory role of STAT6. Inflamm Res 2000;49:275-9 (Pubitemid 30451610)
121. Guillot C, Coathalem H, Chetritt J, et al. Lethal hepatitis after gene transfer of IL-4 in the liver is independent of immune responses and dependent on apoptosis of hepatocytes: a rodent model of IL-4-induced hepatitis. J Immunol 2001;166:5225-35 (Pubitemid 32280739)